Viyash Scientific on Wednesday announced a strategic partnership with Boehringer Ingelheim to strengthen and expand its companion animal portfolio in India, according to a regulatory filing made with stock exchanges on January 22, 2026.
Under the agreement, Alivira Animal Health Limited, a wholly owned subsidiary of Viyash Scientific, has entered into a partnership with Boehringer Ingelheim India Private Limited for the distribution and promotion of Boehringer Ingelheim’s companion animal products across the Indian market. The partnership will cover both urban and rural regions, leveraging Alivira’s distribution network and on-ground presence.
The company stated that the partnership is aimed at addressing the growing demand in India’s pet healthcare segment, which is being driven by rising pet ownership and increasing awareness around preventive animal care and well-being. Through this arrangement, Alivira Animal Health will support the expansion of sales capabilities for Boehringer Ingelheim’s companion animal business in the country.
Viyash Scientific highlighted that the collaboration aligns with its broader strategy to increase its presence in the companion animal segment, while Boehringer Ingelheim noted that the partnership supports its long-term growth plans for animal health operations in India. The agreement is expected to enhance market reach and improve access to companion animal healthcare products nationwide.
The company also reiterated that Sequent Scientific Limited has been officially renamed as Viyash Scientific Limited with effect from January 8, 2026, following approvals from the Registrar of Companies, completing the merger with Viyash Life Sciences Private Limited.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
